Reshaping Misfolding Enzymes

Dr Sam Moxon has been working on a new grant and exploring how to create a spin out innovation biotech company. This work led him to meet Matthias Alder, who we just had to get on the podcast. In this show we hear from Gain Therapeutics CEO Matthias Alder. He is leading a biotech company engaged in the development of a potentially disease-modifying therapy for the treatment of neurodegenerative diseases. Hoping to unlock new treatments for difficult to treat disorders with their SEE-Tx™ supercomputer-driven, drug discovery platform targeting allosteric binding sites. There is a lot of work underway to explore modifying enzymes that have misfolded, losing their functional structure. Misfolding can lead to various diseases, including neurodegenerative disorders like Alzheimer’s and Parkinson’s. Researchers in this field seek, and Gain Therapeutics study the mechanisms behind enzyme misfolding, explore the consequences of misfolding on cellular functions, and develop strategies to correct or reshape these misfolded enzymes. By gaining insights into this process, scientists hope to discover potential therapeutic interventions for treating diseases associated with misfolded enzymes. For more information on Gain Therapeutics visit: https://www.gaintherapeutics.com/ -- A transcript of this show, links and show notes and profile on all our guests are available on our website at https://www.dementiaresearcher.nihr.ac.uk. If you prefer to watch rather than listen, you will find a video version of this podcast on Apple Podcasts, YouTube, and on our website. Leave us a tip: https://dementia-researcher.captivate.fm/support Follow us on social media: https://www.instagram.com/dementia_researcher/ https://www.facebook.com/Dementia.Researcher/ https://www.twitter.com/demrescommunity https://www.linkedin.com/company/dementia-researcher https://bsky.app/profile/dementiaresearcher.bsky.social Download and Register with our Community App: https://www.onelink.to/dementiaresearcher We gratefully acknowledge the support of our funders: Alzheimer’s Association, Race Against Dementia, Alzheimer’s Research UK, Alzheimer’s Society, and the National Institute for Health and Care Research. The views and opinions expressed by guests in this podcast are their own and do not necessarily reflect those of the producers, funders, or sponsors. Subscribe to our sister show 'Dementia Researcher The Blogs': https://podfollow.com/dementia-researcher-blogs